189 related articles for article (PubMed ID: 18705297)
1. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
Hepatogastroenterology; 2008; 55(84):916-20. PubMed ID: 18705297
[TBL] [Abstract][Full Text] [Related]
2. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
J Clin Gastroenterol; 2006 Apr; 40(4):312-6. PubMed ID: 16633103
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study.
Tursi A; Brandimarte G; Elisei W; Picchio M; Forti G; Pianese G; Rodino S; D'Amico T; Sacca N; Portincasa P; Capezzuto E; Lattanzio R; Spadaccini A; Fiorella S; Polimeni F; Polimeni N; Stoppino V; Stoppino G; Giorgetti GM; Aiello F; Danese S
Aliment Pharmacol Ther; 2013 Oct; 38(7):741-51. PubMed ID: 23957734
[TBL] [Abstract][Full Text] [Related]
4. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.
Comparato G; Fanigliulo L; Cavallaro LG; Aragona G; Cavestro GM; Iori V; Maino M; Mazzocchi G; Muzzetto P; Colla G; Sianesi M; Franzé A; Mario FD
Dig Dis Sci; 2007 Nov; 52(11):2934-41. PubMed ID: 17410435
[TBL] [Abstract][Full Text] [Related]
5. Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study.
Tursi A; Di Mario F; Brandimarte G; Elisei W; Picchio M; Loperfido S; Dal Bo' N; Ferrara F; Marcello R; Heras Salvat H; Scarpignato C
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(23):3244-8. PubMed ID: 24338468
[TBL] [Abstract][Full Text] [Related]
6. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W; Aiello F
Int J Colorectal Dis; 2007 Sep; 22(9):1103-8. PubMed ID: 17390144
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
Brandimarte G; Tursi A
Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease.
Gatta L; Di Mario F; Curlo M; Vaira D; Pilotto A; Lucarini P; Lera M; Enkleda K; Franzé A; Scarpignato C
Intern Emerg Med; 2012 Apr; 7(2):133-7. PubMed ID: 21279478
[TBL] [Abstract][Full Text] [Related]
9. Mesalazine for diverticular disease of the colon--a new role for an old drug.
Tursi A
Expert Opin Pharmacother; 2005 Jan; 6(1):69-74. PubMed ID: 15709884
[TBL] [Abstract][Full Text] [Related]
10. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
Dig Dis Sci; 2007 Mar; 52(3):671-4. PubMed ID: 17253134
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.
Iannone A; Ruospo M; Wong G; Barone M; Principi M; Di Leo A; Strippoli GFM
Can J Gastroenterol Hepatol; 2018; 2018():5437135. PubMed ID: 30320044
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
Di Mario F; Aragona G; Leandro G; Comparato G; Fanigliulo L; Cavallaro LG; Cavestro GM; Iori V; Maino M; Moussa AM; Gnocchi A; Mazzocchi G; Franzé A
Dig Dis Sci; 2005 Mar; 50(3):581-6. PubMed ID: 15810646
[TBL] [Abstract][Full Text] [Related]
13. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials.
Picchio M; Elisei W; Tursi A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):291-297. PubMed ID: 30240473
[TBL] [Abstract][Full Text] [Related]
14. Use of mesalazine in diverticular disease.
Di Mario F; Comparato G; Fanigliulo L; Aragona G; Cavallaro LG; Cavestro GM; Franzé A
J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S155-9. PubMed ID: 16885700
[TBL] [Abstract][Full Text] [Related]
15. Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials.
Khan RMA; Ali B; Hajibandeh S; Hajibandeh S
Colorectal Dis; 2018 Jun; 20(6):469-478. PubMed ID: 29520987
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
Tursi A; Brandimarte G; Daffinà R
Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study.
Kruis W; Meier E; Schumacher M; Mickisch O; Greinwald R; Mueller R;
Aliment Pharmacol Ther; 2013 Apr; 37(7):680-90. PubMed ID: 23414061
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials.
Picchio M; Elisei W; Brandimarte G; Di Mario F; Malfertheiner P; Scarpignato C; Tursi A
J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S64-9. PubMed ID: 27622370
[TBL] [Abstract][Full Text] [Related]
19. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.
Tursi A; Papa A; Danese S
Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis.
Festa V; Spila Alegiani S; Chiesara F; Moretti A; Bianchi M; Dezi A; Traversa G; Koch M
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1397-1404. PubMed ID: 28387885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
